What is HC Wainwright’s Estimate for TNYA FY2024 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – HC Wainwright increased their FY2024 earnings estimates for Tenaya Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($1.35) per share for the year, up from their previous estimate of ($1.46). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q4 2024 earnings at ($0.31) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.64) EPS.

TNYA has been the topic of several other reports. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Chardan Capital reduced their target price on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.75.

Tenaya Therapeutics Trading Up 10.4 %

NASDAQ:TNYA opened at $2.76 on Monday. The company has a market capitalization of $217.74 million, a P/E ratio of -1.92 and a beta of 2.34. The business’s 50-day moving average is $2.05 and its 200 day moving average is $3.02. Tenaya Therapeutics has a 12 month low of $1.61 and a 12 month high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07.

Insider Buying and Selling at Tenaya Therapeutics

In other news, CEO Faraz Ali sold 9,748 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.89, for a total value of $28,171.72. Following the completion of the sale, the chief executive officer now owns 188,331 shares in the company, valued at approximately $544,276.59. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 19,539 shares of company stock worth $56,468 over the last quarter. Insiders own 32.76% of the company’s stock.

Institutional Trading of Tenaya Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Tenaya Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock valued at $14,973,000 after buying an additional 403,472 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Tenaya Therapeutics by 90.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 168,565 shares of the company’s stock valued at $882,000 after acquiring an additional 80,212 shares during the period. RA Capital Management L.P. grew its position in Tenaya Therapeutics by 4.5% in the 1st quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock valued at $30,099,000 after acquiring an additional 247,703 shares during the last quarter. Bank of New York Mellon Corp grew its position in Tenaya Therapeutics by 12.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 237,597 shares of the company’s stock valued at $737,000 after acquiring an additional 26,103 shares during the last quarter. Finally, Panagora Asset Management Inc. purchased a new stake in Tenaya Therapeutics in the second quarter worth $164,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.